March 19, 2019
Authored and Edited by Benjamin T. Hemmelgarn; M. Andrew Holtman, Ph.D.
On March 7, 2019, FDA issued draft guidance that describes FDA’s current thinking on nonproprietary names of biological products licensed under section 351 of the Public Health Service Act (PHS Act) that do not include an FDA-designated suffix.
FDA recognizes that licensure of new biological products, including biosimilar and interchangeable products, will continue to grow in the next few years. To reduce confusion and ensure patient safety, FDA promulgated a naming convention in January 2017 for nonproprietary naming of biological products. The 2017 convention included a core name that is designated by the United States Adopted Names Council and is shared between the reference product any biosimilar products, along with a four-letter suffix that would be a unique identifier for each product. The 2017 convention applied retroactively to biological products licensed before the naming convention, but did not apply to interchangeable products because the FDA was still preparing a separate naming convention for interchangeables. Further information about the 2017 convention can be found here.
The draft guidance proposes to remove transition biological products from the scope of the 2017 convention. Additionally, the draft guidance deletes the retroactive effect of the 2017 convention, directing FDA to not modify the names of biological products that were already licensed without a unique suffix. The draft guidance says that removing the retroactive application of the 2017 convention minimizes the burden of product sponsors to rename their products and reduces the opportunity for confusion for healthcare providers and patients that changing a product name might cause. The 2017 convention would still apply to any newly licensed biological products.
Also, the draft guidance proposes a naming convention for interchangeable products that mirrors the 2017 naming convention. Rather than sharing both the same core name and four-letter suffix as the reference product, interchangeable products will instead have a unique four-letter suffix. The distinguishing suffix allows healthcare providers and patients to know exactly which biological product is dispensed and reduces potential name-change confusion if a product is first licensed as a biosimilar and later licensed as an interchangeable product. Instead, the biological product would have the same name if licensed as a biosimilar and then subsequently as an interchangeable product.
FDA also briefly mentioned that vaccines are currently within the scope of the 2017 convention, but FDA is currently evaluating whether the naming convention is required to ensure patient safety given the current identification systems associated with vaccines.
Readers are encouraged to read the draft guidance, also available on FDA's website.
Food and Drug Administration (FDA), FDA Guidance, Biologic License Application (BLA), abbreviated biologic license application (aBLA)
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
4th Spring Pharmaceutical Synchrotron X-Ray Powder Diffraction Workshop
June 10-11, 2024
Basel
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
INCONTESTABLE® Blog
May 3, 2024
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March 2024
April 30, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.